RHOH and neoplasm: tTF-NGR fusion proteins have thrombogenic activity in vitro, selectively bind to their target on endothelial cells (EC), and upon intravenous infusion in human xenograft mouse models induce thrombosis in tumor blood vessels with subsequent tumor growth retardation and regression [6, 7].